Swiss Dx tech company Spinomix lures $3M Series A

Swiss company Spinomix SA secured $3 million in Series A equity financing to further its work using nanoparticles to boost molecular diagnostics technology.

Debiopharm led the round, which also included existing investors as well as a private U.S. investor group.

Spinomix could be worth watching over time because of its technology pedigree and what it is trying to accomplish. The Swiss Federal Institute of Technology of Lausanne spun off the company in November 2004, according to its website. And Spinomix's main platform--dubbed MagPhase--involves the use of magnetic nanoparticles for microfluidics to create a "lab-on-a-chip" that can both automate and miniaturize in vitro diagnostics technologies. Another technology, FibroTrap, is designed to also help improve the diagnostic process by separating targeted cells and molecules within sample collection tubes.

The company bills its tech as a "high-quality, low-cost" way to help prepare biological samples for diagnostic purposes, and also establish more cost-effective and more precise diagnostic tools for patients. Others, such as MIT, are researching the use of nanoparticles to help make cancer biomarkers more visible for diagnostics purposes. And the use of nanotech for diagnostic tools will certainly add to those efforts.

- read the release

Suggested Articles

The randomized, blinded study showed statistically significant improvements in assessments of inattention and brain activity.

U.K.-based surgery robot developer CMR Surgical has begun rolling out its Versius platform to the NHS, completing its first procedures in Europe.

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.